Dr. Jeffrey S. Miller to Present on Progress of GTB-3550 TriKE™ Phase I Trial Accompanying GT Biopharma's Company Presentation at Raymond James Human Health Innovation Conference

Rhea-AI Summary

GT Biopharma announced that Dr. Jeffrey S. Miller will update on the GTB-3550 TriKE™ Phase I trial at the Raymond James Human Health Innovation Conference on June 22, 2021, at 11:20 AM ET. This session will accompany the Company's corporate update presentation. A live webcast will be available on GT Biopharma's website, with a replay archived for 30 days post-event. GT Biopharma focuses on immuno-oncology therapeutics using its proprietary TriKE™ NK cell engager technology, developed in partnership with the University of Minnesota.

BEVERLY HILLS, Calif., June 21, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that Dr. Jeffrey S. Miller will be giving an update on the progress of the GTB-3550 TriKE™ Phase I trial accompanying the Company's corporate update presentation at the upcoming Raymond James Human Health Innovation Conference on Tuesday, June 22, 2021 at 11:20 AM ET.

A live webcast of the event will be available by visiting the "Presentations" page in the Investors section of GT Biopharma's website at www.gtbiopharma.com/news-media/presentations. A replay of the webcast will be archived for 30 days following the presentation.

About GT Biopharma, Inc.

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE™ NK cell engager platform.  Our TriKE™ platform is designed to harness and enhance the cancer killing abilities of a patient's immune system's natural killer cells (NK cells).  GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE™ technology. For more information, please visit gtbiopharma.com.

Investor Contact:
Brendan Payne
Client Lead
Stern Investor Relations, Inc.
brendan.payne@sternir.com 
212-362-1200

Investor and Media Relations Contact
David Castaneda
David@gtbiopharma.com 
414-351-9758

View original content to download multimedia:http://www.prnewswire.com/news-releases/dr-jeffrey-s-miller-to-present-on-progress-of-gtb-3550-trike-phase-i-trial-accompanying-gt-biopharmas-company-presentation-at-raymond-james-human-health-innovation-conference-301316040.html

SOURCE GT Biopharma, Inc.

FAQ

What is the date and time of Dr. Miller's presentation at the Raymond James Conference?

Dr. Miller's presentation will take place on June 22, 2021, at 11:20 AM ET.

How can I watch the GT Biopharma conference presentation?

You can watch the conference presentation via a live webcast on GT Biopharma's website.

What is the focus of GT Biopharma's TriKE™ technology?

GT Biopharma's TriKE™ technology focuses on enhancing the cancer-killing abilities of natural killer (NK) cells.

Where can I find more information about GT Biopharma?

More information about GT Biopharma can be found on their official website at gtbiopharma.com.

What is GTB-3550 TriKE™?

GTB-3550 TriKE™ is a therapeutic candidate being evaluated in a Phase I clinical trial by GT Biopharma.